Latest news with #LanHuang
Yahoo
9 hours ago
- Business
- Yahoo
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
KING OF PRUSSIA, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of innovative molecular glues and bifunctional degraders, today announced the appointment of Dr. Bill Desmarais, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer. "Bill's appointment comes at a pivotal time as SEED advances its differentiated pipeline into clinical trials and expands global strategic partnerships,' said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED. 'His extensive experience in high-impact transactions and strategic licensing will strengthen SEED's ability to accelerate breakthrough therapies in oncology, neurodegeneration, and immunology through our proprietary RITE3™ TPD platform. This appointment underscores SEED's commitment to delivering transformative treatments for patients, partners, and shareholders in 2025 and beyond.' Dr. Desmarais brings more than two decades of leadership in finance, business development, and strategic operations within the biopharma and biotech industries. He previously served as Chief Business Officer at Alchemab Therapeutics and TScan Therapeutics, as well as Vice President of Business Development at Momenta Pharmaceuticals, where he played a critical role in the company's $6.5 billion acquisition by Johnson & Johnson. Earlier in his career, he spent over a decade at Eli Lilly and Company in Search & Evaluation and Corporate Business Development, advancing global partnerships and pipeline expansion. Dr. Desmarais holds a Ph.D. in Biophysics and Structural Biology from Brandeis University, an MBA from the MIT Sloan School of Management, and a B.S. in Biology from Purdue University. "I am excited to join SEED at this transformative moment, working alongside an exceptional team of leaders and innovators,' said Dr. Desmarais. 'I look forward to collaborating with Dr. Lan Huang and her distinguished SEED Co-Founders—Nobel Laureate Avram Hershko and HHMI Investigators Michele Pagano and Ning Zheng—who are at the forefront of breakthrough research in targeted protein degradation. SEED's world-class translational scientists, drug developers, and deeply engaged Board of Directors bring unparalleled expertise across science, finance, risk management, law, and governance. Together, we will advance SEED's groundbreaking strategy, forge key alliances, and drive meaningful impact for patients and stakeholders worldwide.' About SEED TherapeuticsSEED Therapeutics is a biotechnology company dedicated to advancing targeted protein degradation (TPD) through the discovery of novel molecular glues and bifunctional degraders. Powered by its proprietary RITE3™ TPD platform, SEED is developing a pipeline of first-in-class degraders aimed at traditionally undruggable targets across oncology, neurodegeneration, immunology, and virology. Strategic collaborations with industry leaders Eli Lilly and Company and Eisai Co., Ltd. further reinforce SEED's commitment to developing innovative therapies, with its lead RBM39 degrader program expected to enter clinical trials in 2025. For more information, visit Investor Contact: IR@ Contact: PR@
Yahoo
10 hours ago
- Business
- Yahoo
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
KING OF PRUSSIA, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of innovative molecular glues and bifunctional degraders, today announced the appointment of Dr. Bill Desmarais, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer. "Bill's appointment comes at a pivotal time as SEED advances its differentiated pipeline into clinical trials and expands global strategic partnerships,' said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED. 'His extensive experience in high-impact transactions and strategic licensing will strengthen SEED's ability to accelerate breakthrough therapies in oncology, neurodegeneration, and immunology through our proprietary RITE3™ TPD platform. This appointment underscores SEED's commitment to delivering transformative treatments for patients, partners, and shareholders in 2025 and beyond.' Dr. Desmarais brings more than two decades of leadership in finance, business development, and strategic operations within the biopharma and biotech industries. He previously served as Chief Business Officer at Alchemab Therapeutics and TScan Therapeutics, as well as Vice President of Business Development at Momenta Pharmaceuticals, where he played a critical role in the company's $6.5 billion acquisition by Johnson & Johnson. Earlier in his career, he spent over a decade at Eli Lilly and Company in Search & Evaluation and Corporate Business Development, advancing global partnerships and pipeline expansion. Dr. Desmarais holds a Ph.D. in Biophysics and Structural Biology from Brandeis University, an MBA from the MIT Sloan School of Management, and a B.S. in Biology from Purdue University. "I am excited to join SEED at this transformative moment, working alongside an exceptional team of leaders and innovators,' said Dr. Desmarais. 'I look forward to collaborating with Dr. Lan Huang and her distinguished SEED Co-Founders—Nobel Laureate Avram Hershko and HHMI Investigators Michele Pagano and Ning Zheng—who are at the forefront of breakthrough research in targeted protein degradation. SEED's world-class translational scientists, drug developers, and deeply engaged Board of Directors bring unparalleled expertise across science, finance, risk management, law, and governance. Together, we will advance SEED's groundbreaking strategy, forge key alliances, and drive meaningful impact for patients and stakeholders worldwide.' About SEED TherapeuticsSEED Therapeutics is a biotechnology company dedicated to advancing targeted protein degradation (TPD) through the discovery of novel molecular glues and bifunctional degraders. Powered by its proprietary RITE3™ TPD platform, SEED is developing a pipeline of first-in-class degraders aimed at traditionally undruggable targets across oncology, neurodegeneration, immunology, and virology. Strategic collaborations with industry leaders Eli Lilly and Company and Eisai Co., Ltd. further reinforce SEED's commitment to developing innovative therapies, with its lead RBM39 degrader program expected to enter clinical trials in 2025. For more information, visit Investor Contact: IR@ Contact: PR@ in to access your portfolio
Yahoo
28-01-2025
- Business
- Yahoo
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ('SEED'), a biotechnology company pioneering the discovery of molecular glues for targeted protein degradation (TPD) using its proprietary RITE3™ platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations to SEED's ST-01156 molecular glue. This novel agent degrades RBM39, an RNA splicing factor implicated in multiple mechanism-targeted solid tumor indications. SEED is advancing ST-01156 toward an Investigational New Drug (IND) application, with an expected IND filing in the first half of 2025. The Rare Pediatric Disease designation positions SEED to potentially receive an FDA priority review voucher upon approval of ST-01156. SEED also announced that its largest shareholder, BeyondSpring Inc. (NASDAQ: BYSI) ('BeyondSpring'), has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED. Upon completion of the transactions, BeyondSpring is expected to retain approximately 14.4% of SEED's outstanding shares. Pioneering Progress in Targeted Protein Degradation'SEED is rapidly transitioning into a clinical-stage company, with the planned IND filing in the next few months for ST-01156, our novel and potentially best-in-class RBM39 degrader. This marks a significant milestone in our four-year journey to bring innovative therapies to patients,' said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED and BeyondSpring. 'RBM39 is a validated target to address cancers with high unmet medical needs, as highlighted in a recent Nature Reviews Drug Discovery article. At SEED, we are committed to improving patient outcomes through pioneering science and rational drug development.' FDA Recognition and Strategic Growth'The FDA's Rare Pediatric Disease and Orphan Drug designations for ST-01156 represent an important milestone, recognizing its potential to address significant unmet needs in rare oncology indications,' said Jackson Tai, Board Member of SEED. 'These designations may help expedite and reduce the cost of developing, approving, and commercializing this therapeutic agent.' Tai added: 'The transactions announced today will diversify SEED's shareholder base. We believe this is a key step in ensuring that our capital structure and ownership distribution align with institutional investor expectations. SEED is now better positioned to pursue key initiatives, including advancing its clinical pipeline, extending its capital markets options, and maintaining its leadership in the field of targeted protein degradation.' About SEED TherapeuticsSEED Therapeutics is an innovative biotech company focused on discovering and developing targeted protein degradation (TPD) therapeutics, with the mission to transform the treatment of diseases that currently have limited or no treatment options. Leveraging its cutting-edge RITE3™ platform, SEED is at the forefront of molecular glue-based TPD, addressing diseases in oncology and neurodegeneration. Through active collaborations with Eli Lilly and Company and Eisai Co., Ltd., and backed by a comprehensive intellectual property portfolio, SEED has built a robust pipeline of novel drug candidates now approaching clinical development. Visit to learn more. About BeyondSpringBeyondSpring is a global clinical-stage biopharmaceutical company advancing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring is advancing its first-in-class lead asset, Plinabulin, into late-stage clinical development as a direct anti-cancer agent in non-small cell lung cancer (NSCLC) and other cancer indications. Plinabulin binds to a differentiated pocket in tubulin, distinct from other tubulin binders, and is a potent inducer of dendritic cell maturation, which activates both adaptive and innate immunity. In combination with docetaxel, Plinabulin has demonstrated significant overall survival benefits compared to docetaxel alone in second- and third-line NSCLC with EGFR wild type (Lancet Respir Med 2024). Additionally, Plinabulin has shown a significant reduction in severe neutropenia across multiple clinical studies. BeyondSpring's pipeline also includes three preclinical immuno-oncology assets. Visit for more information. Investor Contact:IR@ Media Contact:PR@ in to access your portfolio
